Advertisement
U.S. markets open in 2 hours 24 minutes
  • S&P Futures

    5,202.00
    -12.75 (-0.24%)
     
  • Dow Futures

    39,155.00
    -68.00 (-0.17%)
     
  • Nasdaq Futures

    18,176.75
    -54.75 (-0.30%)
     
  • Russell 2000 Futures

    2,043.90
    -5.90 (-0.29%)
     
  • Crude Oil

    82.55
    -0.17 (-0.21%)
     
  • Gold

    2,157.30
    -7.00 (-0.32%)
     
  • Silver

    25.12
    -0.14 (-0.55%)
     
  • EUR/USD

    1.0848
    -0.0028 (-0.26%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.55
    +0.22 (+1.54%)
     
  • GBP/USD

    1.2682
    -0.0046 (-0.36%)
     
  • USD/JPY

    150.5710
    +1.4730 (+0.99%)
     
  • Bitcoin USD

    63,052.78
    -4,915.95 (-7.23%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,710.50
    -12.05 (-0.16%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

InterMune expects to raise $79.6M from stock sale

InterMune says it is selling 6.5M shares to fund marketing and studies of lung disease drug

NEW YORK (AP) -- Drugmaker InterMune said Wednesday it expects to raise $79.6 million from a stock offering.

The Brisbane, Calif., company said it is selling 6.5 million shares for $13 each.

Shares of InterMune closed at $13.73 Tuesday and the offering is priced at a 5.3-percent discount.

The company's shares lost 86 cents, or 6.3 percent, to $12.87 in morning trading.

InterMune Inc. said it will use the proceeds to fund the marketing and a U.S. clinical trial of its lung disease drug Esbriet. Esbriet is used to treat a terminal lung disease called idiopathic pulmonary fibrosis, or IPF, which causes inflammation and scarring of the lung. InterMune began the drug in Europe in September 2011. It is available in a number of European countries but has not been approved in the U.S.

The proceeds will also fund work on new formulations of Esbriet and studies of the drug in new indications

The underwriters of the offering will have the option to buy another 975,000 shares to cover any over-allotments, potentially raising InterMune's proceeds.

Advertisement